Bisphosphonate-Associated Osteonecrosis of the Jaws: A Guide for the General Dental Practitioner

From Volume 33, Issue 5, June 2006 | Pages 270-275

Authors

Kate Barker

BDS(Hons), MPhil, MFDS RCSEd

Senior House Officer in Oral and Maxillofacial Surgery, University Hospital Aintree, Longmoor Lane, Liverpool, UK

Articles by Kate Barker

Simon Rogers

BDS, MBChB(Hons), FDS RCS(Eng), FRCS(Eng), FRCS(Max), MD

Consultant and Honorary Reader, University Hospital Aintree, Longmoor Lane, Liverpool, UK

Articles by Simon Rogers

Abstract

Bisphosphonates are used most commonly in the management of metastatic malignant disorders to bone and for osteoporosis. The number of patients on treatment is increasing. Although there is clear evidence of medical efficacy, there are increasing numbers of reports concerning bisphosphonate-associated osteonecrosis of the jaws. This side-effect poses significant problems and is very difficult to treat.

The aim of this article is to outline the proposed pathogenesis, incidence, presenting signs and symptoms, and riskfactors. Also, suggestions are made as to the most appropriate measures for prevention and management of bisphosphonate-associated jaw osteonecrosis.

Article